Recent Quotes (30 days)

You have no recent quotes
chg | %

Kane Biotech Inc  

(Public, CVE:KNE)   Watch this stock  
Find more results for KNE
0.0000 (0.00%)
Jan 29 - Close
CVE data delayed by 15 mins - Disclaimer
Currency in CAD
Range     -
52 week 0.03 - 0.12
Open     -
Vol / Avg. 0.00/117,198.00
Mkt cap 4.82M
P/E     -
Div/yield     -
EPS -0.02
Shares 107.02M
Beta 0.74
Inst. own     -

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin -1834.71% -904.89%
Operating margin -1703.00% -906.91%
EBITD margin - -884.76%
Return on average assets -103.87% -65.67%
Return on average equity -187.24% -79.72%
CDP Score - -


Suite 162, 196 Innovation Drive
+1-204-4531301 (Phone)
+1-204-4747552 (Fax)

Website links


Kane Biotech Inc. (Kane) is a biotechnology company. Kane is engaged in the development and commercialization of products that prevent and remove microbial biofilms. The Company�s technology for the chronic wound care market is DispersinB. The Company�s product for the prevention of catheter-associated infections is Aledex. The Company�s products include urinary catheter coating, venous catheter coating, veterinary catheter coating, topical wound gel, and toothpaste and mouthwash. On May 31, 2011, the Company announced that it got a contract from the United States Army Dental and Trauma Research Detachment (USADTRD) to develop an antibiofilm-antimicrobial wound gel formulation consisting of Kane�s DispersinB antibiofilm enzyme and the United States Army�s KSL-W antimicrobial peptide. On February 1, 2011, Kane announced that it had developed the DispersinB enzyme-linked immunosorbent assay (ELISA) kit.

Officers and directors

Philip Renaud Independent Chairman of the Board
Gordon Froehlich President, Chief Executive Officer, Director
Mark Matthewson Chief Financial Officer
Arvind K. Joshi M.D. Director
Mark H. Nawacki Director
Sarah Prichard Director